Moderna secured a UK Court of Appeals victory affirming the validity of a core mRNA patent covering modified uracil bases in COVID-19 vaccines, strengthening its position against Pfizer and BioNTech. Concurrently, the company announced a 10% workforce reduction amid declining vaccine demand and cost-cutting efforts to maintain financial discipline. CEO Stéphane Bancel emphasized a strategic shift away from M&A toward partnerships, aiming to advance promising programs, including those in immuno-oncology with Merck and others, underlining a focus on innovation through collaboration rather than acquisition.